1. Home
  2. IKT vs SLQT Comparison

IKT vs SLQT Comparison

Compare IKT & SLQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.23

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Logo SelectQuote Inc.

SLQT

SelectQuote Inc.

HOLD

Current Price

$0.74

Market Cap

204.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IKT
SLQT
Founded
2008
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
220.5M
204.6M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
IKT
SLQT
Price
$2.23
$0.74
Analyst Decision
Strong Buy
Hold
Analyst Count
5
2
Target Price
$5.00
$2.88
AVG Volume (30 Days)
1.1M
2.2M
Earning Date
03-26-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
57.76
105.00
EPS
N/A
0.11
Revenue
N/A
$1,526,594,000.00
Revenue This Year
N/A
$10.97
Revenue Next Year
N/A
$6.14
P/E Ratio
N/A
$6.47
Revenue Growth
N/A
15.50
52 Week Low
$1.33
$0.56
52 Week High
$2.36
$2.77

Technical Indicators

Market Signals
Indicator
IKT
SLQT
Relative Strength Index (RSI) 71.21 42.79
Support Level $1.63 $0.56
Resistance Level $2.36 $0.94
Average True Range (ATR) 0.16 0.06
MACD 0.02 -0.00
Stochastic Oscillator 72.22 22.24

Price Performance

Historical Comparison
IKT
SLQT

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About SLQT SelectQuote Inc.

SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.

Share on Social Networks: